1.
The safety of statins in clinical practice
by Armitage, Jane, Dr
The Lancet (British edition), 2007, Vol.370 (9601), p.1781-1790
2.
Interpretation of the evidence for the efficacy and safety of statin therapy
by Collins, Rory, Prof
The Lancet (British edition), 2016, Vol.388 (10059), p.2532-2561
3.
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals
by Vollset, Stein Emil, Prof
The Lancet (British edition), 2013, Vol.381 (9871), p.1029-1036
4.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial
by Collins, R
The Lancet (British edition), 2002-07-06, Vol.360 (9326), p.7-22
5.
Lessons from the controversy over statins – Authors’ reply
by Armitage, Jane
The Lancet (British edition), 2016, Vol.388 (10057), p.2237-2238
6.
Misrepresentation of statin safety evidence
by Armitage, Jane
The Lancet (British edition), 2014, Vol.384 (9950), p.1263-1264
7.
Safety and efficacy of statins – Authors' reply
by Collins, Rory
The Lancet (British edition), 2017, Vol.389 (10074), p.1099-1100
8.
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals
by Mihaylova, Borislava
The Lancet (British edition), 2005, Vol.365 (9473), p.1779-1785
9.
Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials
by CLARKE, Robert
Cardiovascular drugs and therapy, 2002, Vol.16 (5), p.411-415
10.
C-reactive protein in the Heart Protection Study – Authors' reply
by Emberson, Jonathan
The Lancet (British edition), 2011, Vol.377 (9781), p.1918-1919
11.
High-risk elderly patients PROSPER from cholesterol-lowering therapy
by Collins, Rory
The Lancet (British edition), 2002-11-23, Vol.360 (9346), p.1618-1619
12.
Effects of folic acid on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals
by Vollset, Stein Emil Stein Emil
The Lancet (British edition), 2013-03-23, Vol.381 (9871)
13.
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions
by Rory Collins
The Lancet (British edition), 2004-03-06, Vol.363 (9411), p.757-767
14.
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
by Collins, Rory
The Lancet (British edition), 2003, Vol.361 (9374), p.2005-2016
15.
Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials
by ARMITAGE, JANE
Heart (British Cardiac Society), 2000-10, Vol.84 (4), p.357-360
16.
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial
by Collins, R
The Lancet (British edition), 2002, Vol.360 (9326), p.23-33
17.
Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors
by Di Angelantonio, Emanuele
The Lancet (British edition), 2017-11-25, Vol.390 (10110), p.2360-2371
18.
The impact of privacy and confidentiality laws on the conduct of clinical trials
by Armitage, Jane
Clinical trials (London, England), 2008-02, Vol.5 (1), p.70-74
19.
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study
by Group, Heart Protection Study Collaborative
The Lancet (British edition), 2011, Vol.377 (9764), p.469-476
20.
Cholesterol Lowering for the Prevention of Stroke
by Armitage, Jane
Practical neurology, 2003-08, Vol.3 (4), p.224-233
